ARTICLE INFO

Article Type

Original Research

Authors

Atashi Shirazi   H. (1 )
Zarif Yeganeh   M. (1 )
Shafi’ie   A. (2 )
Daneshpour   M. S. (1 )
Azizi   F. (3 )
Hedayati   M. (* )






(* ) Obesity Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
(1 ) Obesity Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
(2 ) Milad Hospital, Tehran, Iran
(3 ) Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Correspondence

Address:
Phone:
Fax:
hedayati@endocrine.ac.ir

Article History

Received:  
Accepted:  
ePublished:  

ABSTRACT

Aims Papillary thyroid carcinoma (PTC) and follicular carcinoma (FC) are two main variants of familial non-modularly thyroid carcinoma (FNMTC). TCO gene seems to be effective in this disease. This study was to investigate the effect of loss of heterozygosity of the TCO gene in Iranian families suffering from this disease.
Materials & Methods During the six-months cross sectional study, 10 families affected by familial non-modularly thyroid carcinoma (FNMTC) were selected from Milad hospital (56 subjects including 13 patients with pathologic confirmation and 43 healthy individual of their close families). The DNA content of samples was extracted based on the standard salting out/Proteinase K method. The LOH of the TCO gene was analyzed using 5 markers (D19S916, D19S413, D19S391, D19S568 and D19S865). Following the proliferation of the desired components using PCR, products’ polyacrylamide gel 8% electrophoresis was carried out for determining the genotype.
Results 5.4% of patients (n=3) suffered from the follicular carcinomas and 17.9% (n=10), from the papillary carcinomas. In all of them the LOH in TCO gene area was detected. The frequency of LOH positive cases for each marker was 10.7% (n=6) for D19S916, 12.5% (n=7) for D19S413, 41.1% (n=23) for D19S391, 1.8% (n=1) for D19S568 and 3.6% (n=2) for D19S865.
Conclusion 13.9% of FNMTC cases averagely have LOH in 19p13.2 chromosomal area and genetic loss is considerably more common in papillary carcinomas patients in comparison to follicular carcinomas patients. D19S413 marker is the most informative LOH in FNMTC individuals. The gene(s) located on the 19p13.2 may be associated with FNMTC.


CITATION LINKS